Skip to main content
Top

2006 | OriginalPaper | Hoofdstuk

Wat is de plaats van een selectieve COX-2-remmer ten opzichte van de combinaties van een NSAID met een protonpompremmers of misoprostol?

Auteur : dr. M.T. Nurmohamed

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

De werking van niet-steroïde anti-inflam­matoire geneesmiddelen (NSAID's) berust op een remming van het enzym cyclo-oxygenase (COX). Het COX bepaalt de omzetting van arachidonzuur naar prostaglandinen en tromboxanen en bestaat uit twee iso-enzymen: het cyclo-oxygenase-1 (COX-1) en het cyclo-oxygenase-2 (COX-2). COX-1 is een constitutioneel enzym, dat in de meeste weefsels permanent aanwezig is en betrokken is bij de productie van prostaglandines die de homeostase reguleren van onder andere de maagmucosa, de nieren en de trombocyten. Het COX-1 leidt onder meer tot tromboxaanvorming, dat weer tot vaatvernauwing en trombocytenaggregatie leidt.
Literatuur
go back to reference Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-28.
go back to reference Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class study: A randomized controlled trial. JAMA 2000; 284: 1247-55. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class study: A randomized controlled trial. JAMA 2000; 284: 1247-55.
go back to reference Schnitzer TJ, Burmeister GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutics arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised control trial. Lancet 2004; 364: 665-74. Schnitzer TJ, Burmeister GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutics arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised control trial. Lancet 2004; 364: 665-74.
go back to reference Nielsen OH, Ainsworth M, Csillag C, Rask-Madsen J. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? Aliment Pharmacol Ther 2006; 23: 27-33. Nielsen OH, Ainsworth M, Csillag C, Rask-Madsen J. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? Aliment Pharmacol Ther 2006; 23: 27-33.
go back to reference Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. MEDAL Steering Committee. Related Articles, Links Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-73. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. MEDAL Steering Committee. Related Articles, Links Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-73.
go back to reference Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
go back to reference Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
go back to reference Cannon CP, Curtis SP, Fitzgerald GA, et al. MEDAL Steering committe. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programe: a randomised comparisn. Lancet 2006; 368: 1771-81. Cannon CP, Curtis SP, Fitzgerald GA, et al. MEDAL Steering committe. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programe: a randomised comparisn. Lancet 2006; 368: 1771-81.
go back to reference Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123: 241-49. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123: 241-49.
go back to reference Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; CD002094. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; CD002094.
go back to reference Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn NSAID-gebruik en preventie van maagschade. Utrecht: 2003. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn NSAID-gebruik en preventie van maagschade. Utrecht: 2003.
go back to reference Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006; 113: 1578-87. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006; 113: 1578-87.
go back to reference Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332: 1302-308. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332: 1302-308.
go back to reference Olson NJ. Tailoring arthritis therapy in the wake of the NSAID crises. N Engl J Med 2005; 353: 2578-80. Olson NJ. Tailoring arthritis therapy in the wake of the NSAID crises. N Engl J Med 2005; 353: 2578-80.
Metagegevens
Titel
Wat is de plaats van een selectieve COX-2-remmer ten opzichte van de combinaties van een NSAID met een protonpompremmers of misoprostol?
Auteur
dr. M.T. Nurmohamed
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_1726